Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 6Carcinoma 4Squamous Cell Carcinoma of Head and Neck 3Mouth Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Adenocarcinoma 3Recurrence 2Ovarian Neoplasms 2Neoplasms 2Lung Neoplasms 2Laryngeal Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Skin Neoplasms 1Sinonasal Squamous Cell Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Melanoma 1Liposarcoma 1Hemangiosarcoma 1

Interventions

pembrolizumab 33Cisplatin 22Carboplatin 16Magnetic Resonance Spectroscopy 15Specimen Handling 12Cetuximab 12Radiotherapy, Intensity-Modulated 11Paclitaxel 9Platinum 8Nivolumab 81,2-diaminocyclohexaneplatinum II citrate 8atezolizumab 5Taxes 5Radiotherapy 5Docetaxel 5Biopsy 5Fluorouracil 4(225)Ac-DOTA-c(RGDyK) 4dostarlimab 3cemiplimab 3Radiotherapy, Image-Guided 3Radiation 3Fulvestrant 3Bevacizumab 3tislelizumab 2dehydroftorafur 2budigalimab 2amivantamab 2abemaciclib 2Tiragolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × cemiplimab × 30 days × Clear all
NCT06855212 2026-05-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
22 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06980038 2026-05-13

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

NCT06769698 2026-05-06

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 2 Recruiting
120 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡